1ILMN Stock Chart & Stats
€196.52
-€0.98(-0.57%)
At close: 4:00 PM EDT
€196.52
-€0.98(-0.57%)
Day’s Range― - ―
52-Week Range€49.00 - €284.00
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€35.33B
Enterprise Value€28.37B
Total Cash (Recent Filing)€1.17B
Total Debt (Recent Filing)€2.53B
Price to Earnings (P/E)49.5
Beta0.38
Next Earnings
Oct 29, 2026EPS Estimate
1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding151,000,000
10 Day Avg. Volume100
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€220.30Price Target Upside12.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)4.77
Revenue Forecast (FY)€4.12B
Bulls Say, Bears Say
Bulls Say
NovaSeq X Installed-base GrowthExpanding NovaSeq X placements increase the installed base that generates recurring consumables demand. The high share of transitioned volumes and expected pull-through into 2027 support revenue visibility, deepen customer workflow integration, and strengthen Illumina’s platform economics over the next several quarters.
Strong Profitability And Cash GenerationIllumina’s recovered profitability and substantial free cash flow provide resources to fund research, product development, customer support, and capital allocation without relying entirely on external financing. Strong cash generation also gives the company greater resilience while sequencing demand develops across clinical and research markets.
Clinical Sequencing MomentumClinical consumables growth indicates expanding adoption in a strategically important market with recurring usage after instruments are installed. Combined with raised company guidance, this momentum suggests improving execution and a more durable growth contribution from clinical workflows than from research demand alone.
Bears Say
Research Consumables WeaknessPersistent weakness in research consumables can constrain utilization of Illumina’s installed instruments and offset clinical growth, because consumables are a recurring revenue stream. Continued customer caution and funding uncertainty could therefore slow consolidated growth and delay a broader recovery in sequencing demand.
Moderate Balance-sheet LeverageDebt is manageable alongside current profitability, but leverage reduces financial flexibility if earnings weaken again. Interest obligations and refinancing needs can compete with investment, buybacks, or strategic initiatives, making future operating volatility more consequential for capital allocation and balance-sheet resilience.
Volatile Earnings HistoryThe sharp swing from losses to recovery shows that Illumina’s earnings power has not yet demonstrated consistent durability through different demand conditions. Recent free-cash-flow contraction adds to that concern, since variable profitability and cash conversion can limit confidence in sustained reinvestment capacity.
Illumina News
1ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was €49.00 and its highest was €284.00 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is €35.33B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Jul 30, 2026. The company reported €1.167 earnings per share for the quarter, beating the consensus estimate of €1.092 by €0.075.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.21.
How many shares outstanding does Illumina have?
Illumina has 151,000,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of €1.167 in its last earnings report, beating expectations of €1.092. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in IT:1ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€220.30 (12.10% Upside)
€220.30 (12.10% Upside)
Blogger Sentiment
Neutral
IT:1ILMN Sentiment 58%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth €388.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.27%
12-Months-Change
Fundamentals
Return on Equity
31.08%
Trailing 12-Months
Asset Growth
9.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
1ILMN Company Deck
1ILMN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: Illumina delivered a quarter with strong top-line beats, materially higher instrument placements (especially NovaSeq X), margin outperformance, raised full-year guidance and strengthened multi-omics and BioInsight momentum (Billion Cell Atlas revenue and partners). Headwinds remain—memory and freight costs, inventory/tax timing impacts, and continued weakness in research consumables and some regions—but management has absorbed costs, secured supply, and raised guidance while reaffirming long-term targets. The positive operational and financial beats and the upgraded outlook outweigh the listed challenges.View all IT:1ILMN earnings summaries1ILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
1ILMN Stock 12 Month Forecast
Average Price Target
€220.30
▲(12.10% Upside)